Intensity Therapeutics
INTS
16 hedge funds and large institutions have $4.39M invested in Intensity Therapeutics in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
269% more capital invested
Capital invested by funds: $1.19M → $4.39M (+$3.2M)
78% more funds holding
Funds holding: 9 → 16 (+7)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0.06% more ownership
Funds ownership: 0.09% → 0.15% (+0.06%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$350K |
| 2 |
MFIM
Mesirow Financial Investment Management
Chicago,
Illinois
|
+$144K |
| 3 |
HF
HRT Financial
New York
|
+$134K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$93.8K |
| 5 |
State Street
Boston,
Massachusetts
|
+$61.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HWM
Hohimer Wealth Management
Seattle,
Washington
|
-$597K |
| 2 |
Millennium Management
New York
|
-$101K |
| 3 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$57.7K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.29K |
INTS Hedge Fund Activity: Q4 2023 in Review
16 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Intensity Therapeutics (INTS) for Q4 2023, worth a combined $4.39M — up 269% from $1.19M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new INTS positions and 2 closed out — a net gain of 7 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $350K. The largest seller was Hohimer Wealth Management, cutting an estimated $597K.
- 16 institutional investors held Intensity Therapeutics (INTS) as of Q4 2023, up from 9 in Q3 2023.
- Funds reported $4.39M of Intensity Therapeutics stock for Q4 2023, up 269% quarter-over-quarter.
- 9 funds opened new Intensity Therapeutics positions in Q4 2023 and 2 closed out, a net change of +7 holders.
- The largest Intensity Therapeutics buyer in Q4 2023 was Vanguard Group, an estimated $350K added.
- The largest Intensity Therapeutics seller in Q4 2023 was Hohimer Wealth Management, an estimated $597K sold.
Based on aggregated 13F filings for Q4 2023.